


# PRODUCT INFORMATION



## Midodrine (hydrochloride)

Item No. 17349

**CAS Registry No.:** 43218-56-0  
**Formal Name:** 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]-acetamide, monohydrochloride  
**MF:** C<sub>12</sub>H<sub>18</sub>N<sub>2</sub>O<sub>4</sub> • HCl  
**FW:** 290.7  
**Purity:** ≥95%  
**UV/Vis.:** λ<sub>max</sub>: 290 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Midodrine (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the midodrine (hydrochloride) in the solvent of choice, which should be purged with an inert gas. Midodrine (hydrochloride) is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of midodrine (hydrochloride) in these solvents is approximately 10 and 2 mg/ml, respectively.

Midodrine (hydrochloride) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, midodrine (hydrochloride) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Midodrine (hydrochloride) has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Midodrine is a prodrug form of the α<sub>1</sub>-adrenergic receptor (α<sub>1</sub>-AR) agonist desglymidodrine (Item No. 35608).<sup>1</sup> It is converted to desglymidodrine by enzymatic hydrolysis. Midodrine (5 mg/kg) increases mean arterial pressure (MAP) and decreases heart rate in normotensive rats.<sup>2</sup> Formulations containing midodrine have been used in the treatment of orthostatic hypotension.

### References

1. McCellan, K.J., Wiseman, L.R., and Wilde, M.I. Midodrine. A review of its therapeutic use in the management of orthostatic hypotension. *Drugs Aging* **12**(1), 76-86 (1998).
2. Dabasaki, T., Shimojo, M., Ishikawa, H., et al. Anti-hypotensive effects of M6434, an orally active α<sub>1</sub>-adrenoceptor agonist, in rats. *Jpn. J. Pharmacol.* **59**(2), 145-150 (1992).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/30/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM